Kainos Medicine Inc (284620) - Total Liabilities
Based on the latest financial reports, Kainos Medicine Inc (284620) has total liabilities worth ₩4.18 Billion KRW (≈ $2.84 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Kainos Medicine Inc (284620) asset resilience to evaluate the company's liquid asset resilience ratio.
Kainos Medicine Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Kainos Medicine Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Kainos Medicine Inc total assets.
Kainos Medicine Inc Competitors by Total Liabilities
The table below lists competitors of Kainos Medicine Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gillanders Arbuthnot & Company Limited
NSE:GILLANDERS
|
India | Rs2.95 Billion |
|
Times Guaranty Limited
NSE:TIMESGTY
|
India | Rs1.67 Million |
|
Morgan Sindall Group PLC
LSE:MGNS
|
UK | GBX1.73 Billion |
|
CJ Century Logistics Holdings Bhd
KLSE:7117
|
Malaysia | RM287.14 Million |
|
Nextplat Corp
NASDAQ:NXPL
|
USA | $12.19 Million |
|
Canfor Pulp Products Inc.
TO:CFX
|
Canada | CA$301.50 Million |
|
Gabriel Resources Ltd
V:GBU
|
Canada | CA$23.73 Million |
|
KebNi AB (publ)
ST:KEBNI-B
|
Sweden | Skr37.29 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Kainos Medicine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Kainos Medicine Inc (284620) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kainos Medicine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kainos Medicine Inc (2017–2024)
The table below shows the annual total liabilities of Kainos Medicine Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩8.95 Billion ≈ $6.07 Million |
-3.03% |
| 2023-12-31 | ₩9.23 Billion ≈ $6.26 Million |
-28.27% |
| 2022-12-31 | ₩12.87 Billion ≈ $8.72 Million |
-56.88% |
| 2021-12-31 | ₩29.85 Billion ≈ $20.23 Million |
+33.12% |
| 2020-12-31 | ₩22.43 Billion ≈ $15.20 Million |
+2739.13% |
| 2019-12-31 | ₩789.89 Million ≈ $535.30K |
+2.31% |
| 2018-12-31 | ₩772.06 Million ≈ $523.21K |
+4.31% |
| 2017-12-31 | ₩740.19 Million ≈ $501.62K |
-- |
About Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more